Impact of cerebro-spinal fluid biomarkers of Alzheimer's disease in clinical practice: a multicentric study. (Q53345389)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24162039%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

title

Impact of cerebro-spinal fluid biomarkers of Alzheimer's disease in clinical practice: a multicentric study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24162039%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

0 references

0 references

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24162039%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Eloi Magnin

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24162039%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Emmanuelle Duron

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24162039%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Emilie Beaufils

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24162039%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Audrey GABELLE

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24162039%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Florence Pasquier

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24162039%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

author name string

François Mouton-Liger

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24162039%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

David Wallon

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24162039%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Anne-Cécile Troussière

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24162039%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Rachida Yatimi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24162039%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Vincent de la Sayette

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24162039%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Nathalie Philippi

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24162039%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Bernard Croisile

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24162039%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Philippe Robert

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24162039%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Claire Paquet

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24162039%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Didier Hannequin

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24162039%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Jacques Hugon

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24162039%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

publication date

27 October 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24162039%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24162039%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

volume

261

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24162039%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

page(s)

144-151

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24162039%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24162039%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00415-013-7160-3

28 February 2020

exact match

0 references

cites work

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-7160-3

Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-7160-3

CSF biomarkers in frontotemporal lobar degeneration with known pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-7160-3

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-7160-3

Cerebrospinal fluid biomarker results in relation to neuropathological dementia diagnoses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-7160-3

The primary care diagnosis of dementia in Europe: an analysis using multidisciplinary, multinational expert groups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-7160-3

Impact of diagnostic disclosure in dementia on patients and carers: qualitative case series analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-7160-3

Exacerbated CSF abnormalities in younger patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-7160-3

Intersite variability of CSF Alzheimer's disease biomarkers in clinical setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-7160-3

Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-7160-3

Diagnostic impact of CSF biomarkers in a local hospital memory clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-7160-3

Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-7160-3

Clinico-neuropathological correlation of Alzheimer's disease in a community-based case series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-7160-3

The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-7160-3

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-7160-3

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-7160-3

Quantifying the added value of a diagnostic test or marker

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-7160-3

[Multicenter study on lumbar puncture indication, clinical practice and feasibility].

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-7160-3

Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-7160-3

Clinical criteria for the diagnosis of Alzheimer disease: still good after all these years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-7160-3

11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-7160-3

Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-7160-3

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-7160-3

CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-7160-3

Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-7160-3

The paradox of syndromic diversity in Alzheimer disease.

21 January 2018

1 reference

12 December 2020

CSF biomarkers for Alzheimer's pathology and the effect size of APOE ɛ4.

1 reference

12 December 2020

Early onset Alzheimer's disease is associated with a distinct neuropsychological profile.

1 reference

12 December 2020

Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease

1 reference

12 December 2020

Impact of the 2008-2012 French Alzheimer Plan on the use of cerebrospinal fluid biomarkers in research memory center: the PLM Study

1 reference

12 December 2020

The 2008-2012 French Alzheimer plan: description of the national Alzheimer information system

1 reference

12 December 2020

Alzheimer disease biomarker testing in cerebrospinal fluid: a method to harmonize assay platforms in the absence of an absolute reference standard

1 reference

12 December 2020

Amyloid-β oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer's disease.

1 reference

12 December 2020